Is 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Combined With 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) Superior to PPSV23 Alone for Reducing Incidence or Severity of Pneumonia in Older Adults? A Clin-IQ

Starla Hayward
Lou Ann Thompson
Andrea McEachern

Follow this and additional works at: https://aah.org/jpcrr

Part of the Infectious Disease Commons, and the Respiratory Tract Diseases Commons

Recommended Citation

Published quarterly by Midwest-based health system Advocate Aurora Health and indexed in PubMed Central, the Journal of Patient-Centered Research and Reviews (JPCRR) is an open access, peer-reviewed medical journal focused on disseminating scholarly works devoted to improving patient-centered care practices, health outcomes, and the patient experience.
Is 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Combined With 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) Superior to PPSV23 Alone for Reducing Incidence or Severity of Pneumonia in Older Adults? A Clin-IQ

Starla Hayward, DO,1 Lou Ann Thompson, MLIS, AHIP,2 Andrea McEachern, DO1

1Family Medicine Residency Program, Department of Family Medicine, Oklahoma State University Medical Center, Tulsa, OK
2L.C. Baxter Library, Oklahoma State University Medical Center, Tulsa, OK

Abstract

Pneumonia infection is a significant cause of morbidity and mortality worldwide. In addition to the public health concerns, pneumonia also accounts for a significant cost to the health care system. Currently there are two leading vaccines targeted against Streptococcus pneumoniae: 23-valent pneumococcal polysaccharide vaccine (PPSV23) and 13-valent pneumococcal conjugate vaccine (PCV13). Until recently, the recommendation for adult pneumonia vaccination has been a single dose of PPSV23 for all adults aged 65 years or older. However, concerns were raised regarding the vaccine’s efficacy due to the persistent burden of pneumococcal disease in the elderly population. This paper focuses on two trials that evaluated the safety and efficacy of PCV13 in the adult population. The first study reveals improved immune response with the addition of PCV13 to PPSV23, while the second shows PCV13 was effective in the prevention of vaccine-type community-acquired pneumonia. Both studies observed adequate safety profiles for PCV13 in series with PPSV23 and with PCV13 compared to placebo. (J Patient Cent Res Rev. 2016;3:111-115.)

Search Terms

pneumococcal conjugate vaccine; pneumococcal polysaccharide vaccine; adults; PPSV23; PCV13

Keywords

Clinical Question

In patients 65 years of age or older, is 13-valent pneumococcal conjugate vaccine (PCV13) combined with 23-valent pneumococcal polysaccharide vaccine (PPSV23) superior to PPSV23 alone for reducing the incidence or severity of pneumonia?

Answer

Probably, since PCV13 combined with PPSV23 yields improved immune titers compared to PPSV23 alone. More clinically relevant data showing reduction in incidence or severity of pneumonia is unlikely to become available because of the expense and ethics of conducting the research.

Date answer was determined: September 2015.

Level of evidence: A.

Inclusion Criteria

Humans, age 65 years and older, English language articles, 2008–2015 year of publication.

Exclusion Criteria

Children and adults younger than age 65 years.

Summary of the Issues

Pneumonia infection is a significant cause of morbidity and mortality worldwide, and Streptococcus pneumoniae is currently the most commonly identified pathogen in community-acquired pneumonia. In the United States, S. pneumoniae is responsible for 500,000 cases of pneumonia and 50,000 cases of bacteremia each year, with annual mortality rates of 5–7% and 20%, respectively. Pneumococcal disease in all of its forms is estimated to cause 1.6 million...
deaths globally per year.\(^1\) In addition to the public health concerns, pneumonia also accounts for a significant cost to the health care system.\(^2\)

Currently there are two leading vaccines targeted against \textit{S. pneumoniae}: 23-valent pneumococcal polysaccharide vaccine (PPSV23) and 13-valent pneumococcal conjugate vaccine (PCV13). Pneumococci bacteria are contained within a polysaccharide capsule. The capsules contain antigenic variation, and more than 90 distinct capsular serotypes have been identified. PPSV23 contains antigens from 23 common serotypes, while PCV13 contains antigens from 13 serotypes.\(^3\) Although both vaccines aim to induce immunity against the most common serotypes that cause clinical disease, there is substantial overlap in the antigens contained within each vaccine. Specifically, 12 of the 13 serotypes included in PCV13 are common to PPSV23.\(^2\)

The other major difference between PPSV23 and PCV13 is the design of the vaccine itself. PPSV23 contains capsular polysaccharide antigens. These antigens elicit a T-cell–independent antibody response. The antibodies produced boost activity of phagocytic cells and thereby induce killing of pneumococcus.\(^3\) PCV13 is a conjugate vaccine that combines these capsular polysaccharides with a protein carrier. With the addition of the protein, PCV13 produces a T-cell–dependent immune response with antibody production and the potential for immune memory.\(^3\)

Until recently the recommendation for adult pneumonia vaccination has been a single dose of PPSV23 for all adults aged 65 years or older. However, concerns were raised regarding the vaccine’s efficacy due to the persistent burden of pneumococcal disease in the elderly population. PCV13 was introduced in the pediatric population in 2010 as a replacement for 7-valent pneumococcal conjugate vaccine (PCV7). The conjugated vaccines have proved to be successful at reducing the burden of pneumococcal disease in the pediatric population.\(^3\) New research has focused on PCV13 in the adult population to evaluate both safety and efficacy as well as determine the most appropriate vaccination strategy for prevention of pneumococcal disease.

### Summary of the Evidence

A 2013 study examined the safety and effectiveness of PCV13 in elderly adults who had previously received vaccination with PPSV23. In this study, antipneumococcal opsonophagocytic activity (OPA) titers were measured to evaluate vaccine efficacy. The study, a randomized, modified double-blinded trial, included 936 adults aged 70 years or older who had been previously vaccinated with PPSV23 at least 5 years prior to the trial.\(^4\) Study participants were divided into two groups. One group received a second dose of PPSV23, whereas the other received PCV13. Both groups received a dose of PCV13 1 year later. OPA titers were measured prior to and at 1 month following each vaccine administration. Safety assessments also were performed at 2 weeks, 1 month and 6 months postvaccination.\(^4\)

Study results revealed a significantly greater OPA response for 10 of the 12 common serotypes following vaccination with PCV13 as compared to PPSV23.\(^4\) The study then evaluated immune response following PCV13 administration in both groups 1 year following the initial PCV13 or PPSV23 vaccine. This was performed to assess the impact of initial vaccine choice on response of subsequent vaccinations. Using a 95% confidence interval, OPA titer responses were statistically significantly higher for 11 common serotypes in the group that received PCV13 at enrollment and at 1 year compared to the group receiving PPSV23 initially.\(^4\) The results suggest that a booster dose of PPSV23 given prior to PCV13 may not improve coverage, and it may be more beneficial to administer PCV13 following initial vaccination with PPSV23. PCV13 also had a satisfactory safety profile compared to PPSV23.\(^4\)

Though this report highlighted the limitations of PPSV23 alone in prevention of pneumococcal disease in the elderly, the study is limited by the fact that it was funded by Wyeth Vaccines Research. Wyeth Pharmaceuticals Inc. (Collegeville, PA) manufactures Prevnar 13\(^{®}\), a PCV13. Additionally, while OPA titers are considered a measurement of functional immune response, it is difficult to extrapolate this data into prevention of clinical illness. The primary concern for health care providers is a vaccination strategy that will reduce morbidity and mortality in their patient population.
The Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) was developed to determine the clinical efficacy and safety of PCV13 in the adult population. The study included 84,496 pneumococcal vaccine-naïve adults aged 65 years or older. The randomized, double-blinded, placebo-controlled trial was conducted in the Netherlands, where there were no recommendations for routine pneumococcal vaccination in older adults. Participants were randomly divided into two groups in a 1:1 ratio, either receiving PCV13 or placebo injection. Study participants were then followed for an average of approximately 4 years.

The primary objective of the study was to demonstrate prevention of a first episode of vaccine-type community-acquired pneumonia (CAP). Secondary objectives included prevention of first-episode nonbacteremic and noninvasive vaccine-type CAP (negative cultures of sterile sites) and vaccine-type invasive pneumococcal disease (*S. pneumoniae* present in sterile site). Fifty-nine sentinel centers participated in the study. For patients presenting with symptoms of lower respiratory tract infection, routine diagnostic evaluation was performed. A database was searched for study participation if pneumonia was the suspected diagnosis. For study participants, a urine sample was obtained for testing of serotype-specific urinary antigen. Culture results were monitored for determination of invasive pneumococcal disease. Chest X-rays performed were read at a central location, and radiologists were not informed of patients’ vaccination status.

The CAPiTA study concluded PCV13 was effective in preventing vaccine-type CAP and vaccine-type invasive pneumococcal disease in immunocompetent adults aged 65 years or older for a duration of at least 4 years. Vaccine efficacy was statistically significant in these groups and was found to be 46% in prevention of first-episode vaccine-type CAP, 45% in first-episode nonbacteremic and noninvasive vaccine-type CAP and 75% in vaccine-type invasive pneumococcal disease (Table 1). PCV13 was also found to be safe in the adult population. While there were more local reactions and systemic events in the PCV13 group compared to placebo, there were no documented serious adverse events. Additional endpoints observed during the study included the first episode of nonbacteremic and noninvasive pneumococcal CAP, including nonvaccine serotypes, and the first episode of all-cause CAP. PCV13 efficacy was not found to be significantly different between these groups.

The trial was successful in establishing efficacy and safety for PCV13 in adults for prevention of vaccine-type pneumococcal disease, but this study does have several limitations. Funding and support was namely provided by Pfizer Inc. (New York, NY), which purchased Wyeth, the manufacturer of Prevnar 13, in October 2009. The study also was conducted within one country in a population with little variation in race (98.5% white). Vaccine efficacy may be altered in a more diverse patient population. Additionally, this population was pneumococcal vaccine-naïve. Unlike the Netherlands, the United States has a developed

### Table 1. PCV13 efficacy in first-episode vaccine-type pneumococcal disease

<table>
<thead>
<tr>
<th>Disease Type</th>
<th>PCV13 (N=42,240)</th>
<th>Placebo (N=42,256)</th>
<th>Vaccine efficacy</th>
<th><em>P</em></th>
</tr>
</thead>
<tbody>
<tr>
<td>First-episode vaccine-type CAP</td>
<td>49</td>
<td>90</td>
<td>45.6%</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>First-episode vaccine-type nonbacteremic/noninvasive CAP</td>
<td>33</td>
<td>60</td>
<td>45.0%</td>
<td>0.007</td>
</tr>
<tr>
<td>First-episode vaccine-type invasive pneumococcal disease</td>
<td>7</td>
<td>28</td>
<td>75.0%</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

CAP, community-acquired pneumonia; PCV13, 13-valent pneumococcal conjugate vaccine.

vaccination strategy for pneumonia. Many adults aged 65 years or older have received PPSV23 according to current guidelines. Therefore, while this study shows effectiveness of PCV13, it does not address the question of superiority of PPSV23 in combination with PCV13 compared to PPSV23 alone.

Conclusions
Each pneumonia vaccine has its own set of benefits and limitations. PPSV23 covers a greater number of pneumococcal serotypes, but may not induce effective or lasting immunity. PCV13 seems to produce greater potential for immune memory. However, there are questions of necessity since introduction of PCV13 in the pediatric population has decreased the incidence of these pneumococcal strains in the population as a whole.\(^3\) Regardless, the current vaccination strategy has not been as successful as desired in prevention of pneumococcal disease in the adult population, prompting the U.S. Advisory Committee on Immunization Practices to update its recommendations for pneumococcal vaccination. Current updated guidelines recommend routine administration of PCV13 in series with PPSV23 in all adults 65 years of age or older (Table 2).\(^6\)

Based on studies currently available, the combination of PPSV23 with PCV13 should produce a superior immune response than with PPSV23 alone. Improving immune response should result in an overall reduction in clinical incidence and severity of pneumococcal disease.

Patient-Friendly Recap
- A relatively new vaccine called PCV13 has been effective in preventing pneumonia in children.
- The authors asked whether PCV13, in combination with the commonly used pneumonia vaccine PPSV23, is better at preventing pneumonia in older adults than PPSV23 alone.
- They determined that the research published to date, despite limitations regarding study funding, supports combined use of PCV13 and PPSV23.

Acknowledgments
The authors are grateful for assistance from Elizabeth A. Wickersham, MD, and Laine H. McCarthy, MLIS. Clin-IQ (Clinical Inquiries) is a shared resident/faculty collaborative research process made possible by Oklahoma Shared Clinical & Translational Resources, funded by a National Institutes of Health grant (NIGMS U54GM104938).
Conflicts of Interest
None.

References

© 2016 Aurora Health Care, Inc.